Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
NCT ID: NCT06456593
Last Updated: 2025-09-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
212 participants
INTERVENTIONAL
2024-10-30
2028-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The objective is to evaluate the efficacy and safety of obefazimod compared to placebo as induction and maintenance therapy in subjects with moderately to severely active CD after inadequate response (no response, loss of response, or intolerance) to conventional therapies and/or advanced therapies.
The primary objective for the 48-Week Extension Phase is to evaluate the safety and tolerability of obefazimod compared with placebo in subjects who are enrolled in the Extension Phase.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease
NCT01635621
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy
NCT05470985
Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's Disease
NCT00102921
Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease
NCT02877134
Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease
NCT01203631
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Obefazimod 50mg
Obefazimod 50mg given once-daily (QD) in subjects with moderately to severely active Crohn's disease (CD)
Obefazimod
Obefazimod is administered once-daily in fed condition (ideally at the same time in the morning).
Obefazimod 25mg
Obefazimod 25mg given once-daily (QD) in subjects with moderately to severely active Crohn's disease (CD)
Obefazimod
Obefazimod is administered once-daily in fed condition (ideally at the same time in the morning).
Obefazimod 12.5mg
Obefazimod 12.5mg given once-daily (QD) in subjects with moderately to severely active Crohn's disease (CD)
Obefazimod
Obefazimod is administered once-daily in fed condition (ideally at the same time in the morning).
Placebo
Placebo given once-daily (QD) in subjects with moderately to severely active Crohn's disease (CD)
Placebo
Matching placebo will be administered QD in fed condition (ideally at the same time in the morning).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Obefazimod
Obefazimod is administered once-daily in fed condition (ideally at the same time in the morning).
Placebo
Matching placebo will be administered QD in fed condition (ideally at the same time in the morning).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Able and willing to comply with study visits and procedures as per protocol.
3. Confirmed and documented diagnosis of CD based on endoscopy and histology reports.
4. Moderately to severely active CD as defined by 220 ≤ CDAI ≤ 450 and SES-CD ≥ 6 for ileo-colonic or colonic disease or SES-CD ≥ 4 for isolated ileal disease (per central reading).
5. Documented inadequate response (defined as lack of response or loss of response or intolerance) to at least one of the following treatments: corticosteroids (CS), immunosuppressants (IS), biologic or biosimilar therapies, or janus kinase (JAK) (note: failure to only 5-aminosalicylic acid \[5-ASA\] is not accepted)
6. Women of childbearing potential (WOCBP) and male subjects with WOCBP partner must agree to comply with contraception requirements as stated in section 4.5 (contraception) of this protocol.
7. Subject should be affiliated to a health insurance policy whenever required by a participating country or state.
8. Subject is able and willing to comply with usual public recommendations for sun protection.
Exclusion Criteria
2. Current diagnosis of ulcerative colitis (UC) or indeterminate colitis
3. CD without ileal and/or colonic involvement
4. Untreated active external or perianal fistula or abscess. Stable fistula without abscess and with minimal or low drainage may be enrolled. Recent cutaneous and perianal abscesses are not exclusionary if drained and adequately treated at least 3 weeks before screening colonoscopy or 8 weeks before screening colonoscopy for intra-abdominal abscesses, if no additional surgery is anticipated.
5. Symptomatic bowel stricture and/or stenosis not passable in endoscopy
6. Related to CD surgery:
1. Current stoma or ileoanal pouch
2. More than 2 missing complete segments of the following 5 segments: terminal ileum, right colon, transverse colon, left colon, and sigmoid and rectum
3. Combined previous small bowel resections \> 100 cm
4. Surgical bowel resection within the past 3 months prior to baseline
5. Any other manifestation that might require surgery while enrolled in the study
7. Related to CD treatments:
1. Subject who is currently treated with prohibited concomitant therapies for CD as described in the study protocol
2. Subject who has previously received natalizumab (or any other α4β1 integrin agonist)
3. Subject who has failed more than three advanced therapies for the treatment of CD, or two different mechanisms of action for advanced therapies of CD
8. History of, or active, malignancy including nonmelanoma skin cancer (subjects with a 5-year disease-free survival are eligible)
9. History of colonic cancer or colonic low grade or high grade dysplasia adenomatous polyps, and/or at the screening endoscopy, evidence of low grade or high grade dysplasia adenomatous polyps (fully removed or not)
10. Subject with history of, or diagnosed with, the following during screening: primary sclerosing cholangitis, autoimmune hepatitis, or primary biliary cirrhosis
11. Serious illness requiring hospitalization (not related to CD) within 4 weeks prior to screening
12. Subject with the following infectious conditions:
1. Chronic or recurrent Grade 3 or Grade 4 infection within the last 2 months prior to screening or history of opportunistic infection while not on immunosuppressive therapy
2. Herpes zoster reactivation within the last 2 months prior to screening
3. Active infection at screening or any major episode of infection that required hospitalization or treatment with IV antibiotics within 1 month of screening or during screening (fungal infection of nail beds is allowed)
4. Positive assay or stool culture for pathogens (ova and parasite examination, bacteria) that required treatment per local medical practice or positive test for Clostridioides difficile (C. difficile) toxin at screening.
5. Subject with human immunodeficiency virus (HIV) infection
6. Acute or chronic hepatitis B infection at screening (positive for hepatitis B surface antigen \[HbsAg\] or negative for HbsAg and positive for anti-hepatitis B core antibody in conjunction with detectable hepatitis B virus \[HBV\] deoxyribonucleic acid \[DNA\], or detectable HBV DNA).
7. Acute or chronic hepatitis C virus (HCV) infection as defined by positive for hepatitis C antibody (subjects successfully treated and without recurrence ≥ 1 year with no detectable HCV RNA \[assessed centrally\] are eligible)
8. Active tuberculosis (TB) or untreated latent TB (For subjects with positive or intermediate QuantiFERON test)
13. Subject with uncontrolled ischemic heart disease and/or a history of congestive heart failure
14. Subject with a known family or personal history of congenital or acquired long QT syndrome, or subjects with a marked baseline prolongation of QT/ heart rate-corrected QT (QTc) interval
15. Subject with a history of torsade de pointe (TdP)
16. Acute or chronic clinically relevant pulmonary, hepatic, or renal functional abnormality, encephalopathy, neuropathy or unstable central nervous system pathology such as seizure disorder, or any other clinically significant medical problems.
17. Subjects who received live vaccine within 3 months prior to screening and/or subject who is planning to receive such a vaccine during the study duration
18. Acute or chronic pancreatitis
19. Subject with the following hematological and biochemical laboratory parameters obtained during the screening period:
1. Hemoglobin ≤ 8.0 g/dL1
2. Absolute neutrophil count \< 750/mm3
3. Platelets \< 100,000 /mm3
4. eGFR \< 60 mL/min/1.73 m2
5. Total serum bilirubin \> 1.5 x ULN (except if related to pre-existing and documented Gilbert syndrome)
6. Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 2 x ULN
20. Subject who does not meet the washout period requirements prior to the screening endoscopy as described in the prohibited medication section of the study protocol
21. Use of any investigational or nonregistered product within 3 months or within 5 halflives preceding baseline, whichever is longer, and during the study.
22. Subjects previously treated with obefazimod or with a known hypersensitivity to the active substance or to any of the excipients
23. Illicit drug or alcohol abuse or dependence
24. Subject who is committed to an institution by virtue of an order issued either by the judicial or the administrative authorities
25. Any condition, which in the opinion of the investigator, could compromise the subject's safety or adherence to the study protocol
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abivax S.A.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IMC Gulf Coast Gastroenterology, PC
Fairhope, Alabama, United States
Scottsdale Gastroenterology Specialists
Scottsdale, Arizona, United States
GI Alliance -Gurnee
Sun City, Arizona, United States
Hoag Hospital
Irvine, California, United States
United Medical Doctors
Murrieta, California, United States
Peak Gastroenterology Associates
Colorado Springs, Colorado, United States
Clinical Research Of Brandon, LLC
Brandon, Florida, United States
West Central Gastroenterology d/b/a Gastro Florida
Clearwater, Florida, United States
Auzmer Research
Lakeland, Florida, United States
Research Associates of South Florida, LLC
Miami, Florida, United States
Wellness Clinical Research
Miami Lakes, Florida, United States
Advanced Research Institute, Inc.
New Port Richey, Florida, United States
Sarkis Clinical Trials - Parent
Ocala, Florida, United States
Orlando Health, Inc.
Orlando, Florida, United States
GCP Clinical Research, LLC
Tampa, Florida, United States
Theia Clinical Research Centers, LLC
Temple Terrace, Florida, United States
Northwestern University
Evanston, Illinois, United States
University of Iowa Health Care
Iowa City, Iowa, United States
Lucida Clinical Trials, LLC
New Bedford, Massachusetts, United States
University of Massachusetts, Worcester
Worcester, Massachusetts, United States
Henry Ford Columbus Center
Detroit, Michigan, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
OSU Inflammatory Bowel Disease Center
Hilliard, Ohio, United States
Susquehanna Research Group, LLC
Harrisburg, Pennsylvania, United States
UPMC
Pittsburgh, Pennsylvania, United States
Frontier Clinical Research, LLC
Uniontown, Pennsylvania, United States
Rapid City Medical Center, LLC
Rapid City, South Dakota, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Central Texas Clinical Research, LLC
Austin, Texas, United States
Inquest Clinical Research
Baytown, Texas, United States
Novel Research, LLC
Bellaire, Texas, United States
GI Alliance
Cedar Park, Texas, United States
Baylor University Hospital
Dallas, Texas, United States
GI Alliance - Garland
Garland, Texas, United States
Texas Digestive Specialists
Harlingen, Texas, United States
Houston Methodist Hospital
Houston, Texas, United States
GI Alliance - Gurnee
Mansfield, Texas, United States
Southern Star Research Institute, LLC
San Antonio, Texas, United States
Tyler Research Institute, LLC
Tyler, Texas, United States
University of Utah
Salt Lake City, Utah, United States
Richmond VA Medical Center
Richmond, Virginia, United States
Gastroenterology Consultants of Southwest Virginia.
Roanoke, Virginia, United States
University of Washington
Seattle, Washington, United States
Hopital Universitaire de Bruxelles - Hopital Erasme
Brussels, , Belgium
AZ Maria Middelares
Ghent, , Belgium
Universitair Ziekenhuis Gent
Ghent, , Belgium
UZ Leuven
Leuven, , Belgium
Centre Wallonie Picarde
Tournai, , Belgium
CHU UCL Namur
Yvoir, , Belgium
SurGal Clinic s.r.o.
Brno, , Czechia
Vojenska nemocnice Brno
Brno, , Czechia
Hepato-Gastroenterologie HK s.r.o.
Hradec Králové, , Czechia
PreventaMed s.r.o.
Olomouc, , Czechia
ISCARE a.s.
Prague, , Czechia
Nemocnice Slany
Slaný, , Czechia
CHU Amiens
Amiens, , France
CHU Besançon - Hôpital Jean Minjoz
Besançon, , France
CHU Clermont Ferrand - Hopital d'Estaing
Clermont-Ferrand, , France
Hôpital Henri Mondor
Créteil, , France
CHU Dijon - Hôpital Bocage Central
Dijon, , France
CHU de Grenoble - Hôpital Michallon
Grenoble, , France
Centre Hospitalier Départemental Vendée - Les Oudairies
La Roche-sur-Yon, , France
Hôpital Bicêtre
Le Kremlin-Bicêtre, , France
CHU Lille - Hôpital Claude Huriez
Lille, , France
Hôpital Nord - CHU Marseille
Marseille, , France
Hopital Saint Eloi
Montpellier, , France
CHU Nantes - Hôtel Dieu
Nantes, , France
Institut des MICI
Neuilly-sur-Seine, , France
CHU Nice - Hôpital de l'Archet 2
Nice, , France
CHU Bordeaux - Hôpital Haut-Lévêque
Pessac, , France
Centre Hospitalier Lyon Sud
Pierre-Bénite, , France
CHU Saint Etienne - Hôpital Nord
Saint-Etienne, , France
Hopital Rangueil
Toulouse, , France
Hôpital de Brabois
Vandœuvre-lès-Nancy, , France
Charite-Campus Benjamin Franklin Medizin.Klin.I
Berlin, , Germany
Krankenhaus Waldfriede e. V.
Berlin, , Germany
Universitaetsklinikum Brandenburg an der Havel
Brandenburg, , Germany
Universitaetsklinikum Erlangen
Erlangen, , Germany
Universitaetsklinikum Frankfurt Goethe-Universitaet
Frankfurt am Main, , Germany
Hamburgisches Forschungsinstitut fuer Chronisch Entzuendliche Darmerkrankungen
Hamburg, , Germany
Medizinische Hochschule Hannover
Hanover, , Germany
Universitaetsklinikum Heidelberg
Heidelberg, , Germany
Universitaetsklinikum Schleswig-Holstein - Campus Kiel
Kiel, , Germany
St. Marienkrankenhaus
Ludwigshafen, , Germany
LMU - Campus Grosshadern
München, , Germany
Universitaetsklinikum Ulm
Ulm, , Germany
Bekes Varmegyei Kozponti Korhaz
Békéscsaba, , Hungary
Obudai Egeszsegugyi Centrum Kft.
Budapest, , Hungary
Pannonia Maganorvosi Centrum
Budapest, , Hungary
Semmelweis Egyetem
Budapest, , Hungary
Semmelweis Egyetem
Budapest, , Hungary
Gyongyosi Bugat Pal Korhaz
Gyöngyös, , Hungary
Clinfan Szolgaltato Kft.
Szekszárd, , Hungary
Fejer Varmegyei Szent Gyorgy Egyetemi Oktato Korhaz
Székesfehérvár, , Hungary
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS
Bologna, , Italy
Azienda Ospedaliera Universitaria Renato Dulbecco di Catanzaro
Catanzaro, , Italy
Ospedale San Raffaele
Milan, , Italy
Ospedale Sacro Cuore Don Calabria
Negrar, , Italy
Fondazione IRCCS Policlinico San Matteo
Pavia, , Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, , Italy
Università Campus Bio-Medico di Roma
Roma, , Italy
Istituto Clinico Humanitas
Rozzano, , Italy
IRCCS Ospedale Casa Sollievo della Sofferenza
San Giovanni Rotondo, , Italy
Amsterdam UMC, Locatie AMC
Amsterdam, , Netherlands
Maastricht University Medical Center
Maastricht, , Netherlands
Radboud UMC
Nijmegen, , Netherlands
ETZ Elisabeth
Tilburg, , Netherlands
Bernhoven Uden
Uden, , Netherlands
Centrum Medyczne Medis
Bydgoszcz, , Poland
NZOZ Centrum Medyczne KERmed
Bydgoszcz, , Poland
Santa Sp. z o.o. Sp. K Polimedica PTG Kielce
Kielce, , Poland
Mz Badania Slowik Zymla Sp J
Knurów, , Poland
Centrum Medyczne Plejady
Krakow, , Poland
AMICARE spółka z ograniczoną odpowiedzialnością spółka komandytowa
Lodz, , Poland
ALLMEDICA sp. z o. o.
Nowy Targ, , Poland
Twoja Przychodnia Opolskie Centrum Medyczne
Opole, , Poland
Trialmed CRS
Piotrkow Trybunalski, , Poland
NSZOZ Termedica - Centrum Badan Klinicznych
Poznan, , Poland
SOLUMED Centrum Medyczne
Poznan, , Poland
Twoja Przychodnia PCM
Późna, , Poland
Gabinet Lekarski Bartosz Korczowski
Rzeszów, , Poland
Kiepury Clinic MAŁGORZATA JARNOT SPECJALISTYCZNA PRAKTYKA GINEKOLOGICZNO-POŁOŻNICZA
Sosnowiec, , Poland
DC-MED
Swidnica, , Poland
Twoja Przychodnia-Szczecinskie Centrum Medyczne Sp. z o. o.
Szczecin, , Poland
Centrum Zdrowia MDM
Warsaw, , Poland
Medical Network Spolka z o.o
Warsaw, , Poland
NZOZ VIVAMED Jadwiga Miecz
Warsaw, , Poland
Melita Medical Sp. Z O. O.
Wroclaw, , Poland
ETG Zamosc
Zamość, , Poland
Samodzielny Publiczny Zakład Opieki Zdrowotnej w Lecznej
Łęczna, , Poland
S.C Delta Health Care S.R.L
Bucharest, , Romania
SC Centrul Medical Medicum SRL, Specialitatea Gastroenterologie
Bucharest, , Romania
Spitalul Clinic Colentina
Bucharest, , Romania
S.C Pelican Impex S.R.L
Oradea, , Romania
Valahia Medical SRL
Ploieşti, , Romania
Fakultna nemocnica s poliklinikou F.D. Roosevelta
Banská Bystrica, , Slovakia
Cliniq s.r.o.
Bratislava, , Slovakia
Endomed, s.r.o.
Košice, , Slovakia
KM Management spol. s r.o.
Nitra, , Slovakia
Gastro I, s.r.o.
Prešov, , Slovakia
Penta hospitals SK, a.s.
Rimavská Sobota, , Slovakia
Centro Medico Teknon
Barcelona, , Spain
Hospital Universitario Reina Sofia
Córdoba, , Spain
Hospital Universitario de Fuenlabrada
Fuenlabrada, , Spain
Hospital General Juan Ramon Jimenez
Huelva, , Spain
Hospital Universitario de Gran Canaria Dr. Negrin
Las Palmas de Gran Canaria, , Spain
Clinica Gaias - Santiago
Santiago de Compostela, , Spain
Hospital Universitario Virgen del Rocio
Seville, , Spain
Hospital Clinico Universitario de Valencia
Valencia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Nathaniel Winstead, MD
Role: primary
S. Jaffrey Kazi, MD
Role: primary
Chirag Trivedi, MD
Role: primary
Caroline Hwang, MD
Role: primary
John Hong, MD
Role: primary
Bhaktasharan Patel, MD
Role: primary
German Alvarez, MD
Role: primary
Tejinder Glamour, MD
Role: primary
Niaz Ausaf, MD
Role: primary
Alexander Veloso, MD
Role: primary
Lucky Flores, MD
Role: primary
Curtis Freedland, MD
Role: primary
Vishnu Reddy, MD
Role: primary
Udayakumar Navaneethan, MD
Role: primary
Alan Weintraub, MD
Role: primary
Zubair Farooqui, MD
Role: primary
Emanelle Bellaguarda, MD
Role: primary
Steven Polyak, MD
Role: primary
Jason Reich, MD
Role: primary
Abbas Rupawala, MD
Role: primary
Najwa El-Nachef, MD
Role: primary
Corey Siegel, MD
Role: primary
Madalina Butnariu, MD
Role: primary
Adnan Ahmad, MD
Role: primary
Marc Schwartz, MD
Role: primary
Marc Happe, MD
Role: primary
Blake Jones, MD
Role: primary
Audrey Bennett, MD
Role: primary
Cynthia Brinson, MD
Role: primary
Haider Afzal, MD
Role: primary
Moazzam Sana, MD
Role: primary
Ryan Cho, MD
Role: primary
Themistocles Dassopoulos, MD
Role: primary
Harry Sarles, MD
Role: primary
Nolan Perez, MD
Role: primary
Bincy Abraham, MD
Role: primary
Moustafa Youssef, MD
Role: primary
Jeff Bullock, MD
Role: primary
George Aaron DuVall, MD
Role: primary
John Valentine, MD
Role: primary
William Pandak, MD
Role: primary
Nirish Shah, MD
Role: primary
Scott Lee, MD
Role: primary
Denis Franchimont, MD
Role: primary
Nele Deprez, MD
Role: primary
Triana Lobaton Ortega, MD
Role: primary
Bram Verstockt, MD
Role: primary
Lena Capirchio, MD
Role: primary
Jean-François Rahier, MD
Role: primary
Jan Ulbrych, MD
Role: primary
David Stepek, MD
Role: primary
Miroslava Volfova, MD
Role: primary
Jiri Pumprla, MD
Role: primary
Milan Lukas, MD
Role: primary
Martin Peterka, MD
Role: primary
Mathurin Fumery, MD
Role: primary
Lucine Vuitton, MD
Role: primary
Anthony Buisson, MD
Role: primary
Mathieu Uzzan, MD
Role: primary
Maeva Charkaoui, MD
Role: primary
Marianne Hupe, MD
Role: primary
Morgane Amil, MD
Role: primary
Aurelien Amiot, MD
Role: primary
Maria Nachury, MD
Role: primary
Melanie Serrero, MD
Role: primary
Romain Altwegg, MD
Role: primary
Catherine Le Berre, MD
Role: primary
Xavier Treton, MD
Role: primary
Adrien Nicolau, MD
Role: primary
David Laharie, MD
Role: primary
Stephane Nancey, MD
Role: primary
Xavier Roblin, MD
Role: primary
Cyrielle Gilletta de Saint Joseph, MD
Role: primary
Benedicte Caron, MD
Role: primary
Britta Siegmund, MD
Role: primary
Carsten Buening, MD
Role: primary
Stefan Lueth, MD
Role: primary
Raja Atreya, MD
Role: primary
Irina Blumenstein
Role: primary
Stefanie Howaldt, MD
Role: primary
Ursula Seidler, MD
Role: primary
Annika Gauss, MD
Role: primary
Stefan Schreiber, MD
Role: primary
Tanja Kuehbacher, MD
Role: primary
Helga Toeroek, MD
Role: primary
Jochen Klaus, MD
Role: primary
Marta Varga, MD
Role: primary
Robert Sike, MD
Role: primary
Robert Schnabel, MD
Role: primary
Pal Miheller, MD
Role: primary
Zsolt Tulassay, MD
Role: primary
Gabor Makai, MD
Role: primary
Agnes Salamon, MD
Role: primary
Roland Fejes, MD
Role: primary
Paolo Gionchetti, MD
Role: primary
Francesco Luzza, MD
Role: primary
Silvio Danese, MD
Role: primary
Angela Variola, MD
Role: primary
Antonio Di Sabatino, MD
Role: primary
Antonio Gasbarrini, MD
Role: primary
Michele Cicala, MD
Role: primary
Alessandro Armuzzi, MD
Role: primary
Fabrizio Bossa, MD
Role: primary
Geert D'Haens, MD
Role: primary
Marieke Pierik, MD
Role: primary
Marjolijn Duijvestein, MD
Role: primary
Maurice Lutgens, MD
Role: primary
Moniek Gorter, MD
Role: primary
Maria Klopocka, MD
Role: primary
Patryk Korga, MD
Role: primary
Dariusz Solowiej, MD
Role: primary
Maciej Zymla, MD
Role: primary
Monika Augustyn, MD
Role: primary
Rafal Drozda, MD
Role: primary
Mikolaj Krzyzanowski, MD
Role: primary
Marzena Kwinto, MD
Role: primary
Beata Neneman, MD
Role: primary
Jacek Paszkowski, MD
Role: primary
Magdalena Andrzejewska, MD
Role: primary
Ewa Furmanowska-Ladorska, MD
Role: primary
Bartosz Korczowski, MD
Role: primary
Lukasz Firkowski, MD
Role: primary
Witold Marczynski, MD
Role: primary
Beata Gawdis Wojnarska, MD
Role: primary
Marek Woynarowski, MD
Role: primary
Jaroslaw Kierkus, MD
Role: primary
Robert Petryka, MD
Role: primary
Jaroslaw Leszczyszyn, MD
Role: primary
Katarzyna Wojcik, MD
Role: primary
Lukasz Wolanski, MD
Role: primary
Camelia Chioncel, MD
Role: primary
Theodor Alexandru Voiosu, MD
Role: primary
Radu-Bogdan Mateescu, MD
Role: primary
Alin-Horea Suta, MD
Role: primary
George Stancu, MD
Role: primary
Jozef Balaz, MD
Role: primary
Tibor Hlavaty, MD
Role: primary
Miroslav Fedurco, MD
Role: primary
Milos Gregus, MD
Role: primary
Bohus Bunganic, MD
Role: primary
Jan Zachar, MD
Role: primary
Miquel Sans Cuffi, MD
Role: primary
Eva Maria Iglesias Flores
Role: primary
Fernando Bermejo San Jose, MD
Role: primary
Elena Gomez Delgado, MD
Role: primary
Daniel Sebastian Ceballos Santos, MD
Role: primary
Ana Alvarez Castro, MD
Role: primary
Eduardo Leo Carnerero, MD
Role: primary
Carles Suria Bolufer, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ABX464-202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.